MAINTENANCE NOTIFICATION: There is a scheduled maintenance that will result in intermittent service interruption between 2pm and 5pm EST on Friday, April 3rd 2020
Menu
Search
Home > Courses > Is There Ongoing Virus Replication During Apparently Suppressive ART?

Is There Ongoing Virus Replication During Apparently Suppressive ART?

Is There Ongoing Virus Replication During Apparently Suppressive ART?
Sorry, this learning module is not available for mobile devices.
This video is available at the Physicians Research Network website.

Original Release Date: 6/14/2011
Review Date: 6/14/2011
Presenters
  • Teresa Evering, MD
    Associate Attending Physician
    Rockefeller University Hospital
  • Martin Markowitz, MD
    Clinical Director and Staff Investigator, the Aaron Diamond AIDS Research Center
    Aaron Diamond Professor at the Rockefeller University
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Discuss the effects of HIV-1 on the GI tract and immune reconstitution after cART is given.
  2. Know whether persistent CD4 depletion and immune activation in the lamina propria of the lower GI tract is due to ongoing virus replication.
  3. Appreciate whether 5-drug ART begun during acute and early infection results in virologic and immunologic benefit when compared to standard 3-drug ART?
Presenter Bios
Teresa Evering, MD
Teresa Evering, MD, is an Associate Attending Physician at the Rockefeller University Hospital and Research Scientist at the ADARC, mentored by Dr. David Ho and Clinical Director of ADARC, Dr. Martin Markowitz. Dr. Evering's research has focused on questions surrounding the potential for ongoing HIV replication during suppressive highly active antiretroviral therapy, and her current work focuses primarily on the central nervous system, an important sanctuary site for HIV-1.
Martin Markowitz, MD
Martin Markowitz is a graduate of Stanford Medical School, completed his postgraduate training in Hematology/Oncology at Cornell Medical College, and Infectious Diseases at New York University. He has worked at the Aaron Diamond AIDS Research Center (ADARC) since 1992, where his research interests have included the pathogenesis and treatment of acute HIV-1 infection, the fitness and transmission of drug resistant HIV-1, and investigations of novel antiretroviral agents as well as pathogenesis-based interventional trials. More recently, research interests have expanded to understanding mechanisms and consequences of immune activation in HIV-infected and uninfected injection drug users and investigating novel approaches to using antiretroviral agents as prevention. Dr. Markowitz has co-authored over 140 peer-reviewed publications in medical journals, serves as a peer reviewer for a wide spectrum of journals and currently chairs the AIDS Research Review Committee for the National Institutes of Health and private funding institutions.
PRN Learning Modules